[Radiotherapy and ECRF 159 (NCS 129943) in the treatment of inoperable soft-tissue sarcoma (author's transl)].
D000008:Abdominal Neoplasms / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000139:chemically induced; D004941:Esophagitis / Q000139:chemically induced; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011832:Radiation Injuries; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D012509:Sarcoma / Q000188:drug therapy* / Q000532:radiotherapy; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D010879:Piperazines
Strahlentherapie und ICRF 159 (NSC 129943) in der Behanlung inoperabler Weichteilsarkome